Changing the Future of PNH Care Through Global Collaboration – The Max Foundation
The Max Foundation shared a post on LinkedIn:
“For physicians like Dr. Mipsang Lama in Nepal, there was a time when the rare and devastating blood disorder of Paroxysmal Nocturnal Hemoglobinuria (PNH) could be identified but not truly treated.
Care meant repeated transfusions, temporary stabilization, and watching patients live with constant uncertainty.
Then, thanks to our partnership with Novartis Global Health and the International PNH Interest Group, access to treatment and training changed that!
Within weeks, patients began regaining strength. Conversations shifted from survival to possibility.
For Dr. Lama, it was more than a clinical change. It was the ability to finally offer hope alongside care.
He shared, ‘To those working in global health and rare disease access, your work has a deeply human impact. PNH may be rare, but the suffering it causes is real and significant. Today, for the first time, we can say with confidence that ‘it is treatable.’ ”
Stay updated with Hemostasis Today.
-
Aug 24, 2026, 16:36Alejandro González Veliz։ Does ACC/AHA Lesion Complexity Still Matter?
-
Aug 24, 2026, 16:21Kamlesh Darji: Paraneoplastic Syndromes – Tumor with or without Mediator
-
Aug 24, 2026, 15:15Jim Hoffman: Could Targeting NETosis Reduce Long-Term Risk After STEMI?
-
Aug 24, 2026, 14:58Danny Hsu: Rethinking Bleeding Risk in Patients on Anticoagulation
-
Aug 24, 2026, 14:18The Way to a Safer Workplace for People With Bleeding Disorders – EHC
-
Aug 24, 2026, 14:09Stuart Andrew: NHS Blood and Transplant Strengthening the Blood Supply
-
Aug 24, 2026, 14:05Edward Lee Carter: Anticoagulation Stewardship is Moving From Recommendation to Measurement
-
Aug 24, 2026, 13:58Meera Chitlur: Transforming Care for Heavy Menstrual Bleeding at Children’s Hospital of Michigan
-
Aug 24, 2026, 13:49Heghine Khachatryan: Prepartum Acquired Hemophilia A and the Challenge of Maternal and Neonatal Bleeding